Prof Nagy Habib

Prof Nagy Habib
Prof Nagy Habib
Head of R&D and CMO
MiNA Therapeutics

Presentations at Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine

Profile of Prof Nagy Habib

Professor Habib is a leading academic hepatobiliary surgeon, Head of Surgery at the Hammersmith Hospital Campus, Imperial College London and Founder, Head of R&D and Chief Medical Officer for MiNA Therapeutics Ltd. His research programme evolved from research in oncogenes to tumour suppressor genes, epigenetic modification, gene therapy, stem cell therapy, RNA, and saRNA and RNA aptamers. Professor Habib is the first to trial a first-in-human and a first-in-class RNA oligonucleotide (MTL-CEBPA) in patients with liver cancer, among other accomplishments.
Professor Habib co-founded several biotech companies, including: EMcision (acquired by Boston Scientific), OmniCyte, MiNA Therapeutics, Apterna Therapeutics, Medeva (acquired by Celltech), and Bioenvision (acquired by Genzyme).


Please login to send a Private Message

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021